<DOC>
	<DOCNO>NCT02385851</DOCNO>
	<brief_summary>This randomize , double-blind , single-dose , 2-period crossover study healthy subject assess PK , PD , safety ( include immunogenicity ) single 6 mg subcutaneous ( SC ) injection CHS-1701 compare single 6 mg SC dose Neulasta® .</brief_summary>
	<brief_title>Comparison Pharmacokinetic Pharmacodynamic Biosimilarity CHS-1701 ( Coherus Pegfilgrastim ) With Neulasta® ( Pegfilgrastim )</brief_title>
	<detailed_description>This randomize , double-blind , single-dose , 2-period crossover study healthy subject assess PK , PD , safety ( include immunogenicity ) single 6 mg subcutaneous ( SC ) injection CHS-1701 compare single 6 mg SC dose Neulasta® . After screen , eligible subject randomly assign 1 2 treatment sequence ; CHS-1701 follow Neulasta® ( Sequence A ) Neulasta® follow CHS-1701 , Sequence B ) . Treatments space minimum 6 week apart ( 8 week ) . Subjects admit Clinical Pharmacology Unit ( CPU ) Day -1 ( Period 1 ) confine Hour 96 postdose ( total approximately 4.5 day 5 night ) . Blood sample collect specified time point postdose plasma PK PD measurement subject closely monitored safety . Following discharge morning Day 5 ( Period 1 ) subject return clinic additional PK , PD safety follow -- daily Day 9 state interval time point thereafter . The single dose alternate blind study drug give 6 ( 8 ) week observation washout procedure repeat ( Period 2 ) . A Follow Visit take place 41 ( ±1 ) day second dose .</detailed_description>
	<criteria>1 . Adult male female age 18 50 inclusive 2 . Body weight &gt; 50 kg ( 110 lb . ) body mass index 18 32 kg/m2 inclusive 3 . Medically healthy clinically insignificant finding base medical history , 12lead ECG , physical examination 4 . Negative urine pregnancy test woman childbearing potential 1 . Previous exposure pegfilgrastim filgrastim , know allergy PEG ( polyethylene glycol ) 2 . Chemistry hematology value outside protocol specify range 3 . Current previous cancer , diabetes , clinically significant cardiovascular , metabolic , renal , hepatic , gastrointestinal , hematologic , respiratory , dermatological , neurological , psychiatric , disorder 4 . History chronic acute respiratory illness within past 4 week 5 . Positive urine drug alcohol screen unwillingness abstain alcohol recreational drug duration study participation 6 . No prescription nonprescription drug study 7 . Participation investigational clinical study within 30 day prior screen 8 . Known suspected allergic reaction latex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>